EGFR and non-small cell lung carcinoma: For instance, a phase I trial of personalized neoantigen peptide vaccine (PPV) in advanced NSCLC patients established safety and feasibility, yielding notable clinical outcomes, including one complete response and six partial responses, particularly among EGFR-mutated patients (12).